Bertil Lindmark is the current Chief Scientific Officer and Executive Director of R&D at Almirall and member of Almirall’s Management Board. He has been in this position since January 2011 and in that time filed aclidinum bromide in the Genuair inhaler device for the treatment of COPD in EU and in the US 2011, as well as filing linaclotide for the treatment of IBS-C in EU 2011. Both filings were approved in 2012.
Prior to this, Bertil held the position as VP and Head of Clinical Development AstraZeneca Japan, with cross-therapy area accountabilities 2009-2010. He also worked as VP Clinical Development Respiratory and Inflammation Therapy Area in AstraZeneca 2001-2009. Developed Symbicort and Symbicort SMART therapy, and was accountable for taking more than 25 NCEs into man.Between 1991 and 2001, he held clinical roles in Astra and AstraZeneca, with drug development experience from all phases and all geographies, covering mainly respiratory, gastroenterology and rheumatology.
In this interview Bertil Lindmark praises the manoeuvrability of smaller pharma companies. He argues that the current in vivo models need revising and that single-point interventions may not be the best strategy for pharmaceuticals
Download PDF Attachment